Shield Therapeutics plc (LON:STX – Get Free Report) dropped 4.9% during mid-day trading on Thursday . The company traded as low as GBX 3.17 ($0.04) and last traded at GBX 3.22 ($0.04). Approximately 2,220,797 shares traded hands during trading, a decline of 17% from the average daily volume of 2,680,130 shares. The stock had previously closed at GBX 3.38 ($0.04).
Shield Therapeutics Trading Down 5.5 %
The firm has a market capitalization of £22.91 million, a price-to-earnings ratio of -73.25 and a beta of 1.42. The company has a debt-to-equity ratio of 3,691.50, a quick ratio of 2.16 and a current ratio of 1.05. The company has a 50-day moving average price of GBX 2.71 and a 200-day moving average price of GBX 3.31.
About Shield Therapeutics
Shield is a commercial-stage specialty pharmaceutical company that delivers Accrufer®/Feraccru® (ferric maltol), an innovative and differentiated pharmaceutical product, to address a significant unmet need for patients suffering from iron deficiency, with or without anemia. The Company has launched Accrufer® in the U.S.
See Also
- Five stocks we like better than Shield Therapeutics
- The Significance of a Trillion-Dollar Market Cap Goes Beyond a Number
- IBM’s AI Bet Pays Off—What’s Next for Investors?
- Dividend King Proctor & Gamble Is A Buy On Post-Earnings Weakness
- 3 Reasons to Treat AMD’s Drop as an Entry Opportunity
- What Investors Need to Know to Beat the Market
- Qualcomm’s Post-Earnings Dip: A Prime Buying Opportunity?
Receive News & Ratings for Shield Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shield Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
